This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
QIAGEN (QGEN) Launches PCR Test, Expands Testing Portfolio
by Zacks Equity Research
QIAGEN (QGEN) aims to expand its NeuMoDx testing menu with the latest test launch and label extension.
QIAGEN (QGEN) Launches COVID-19 Antigen Test With Ellume
by Zacks Equity Research
QIAGEN (QGEN) starts commercializing latest test after filing for FDA emergency use authorization (EUA) for symptomatic patients.
Should You Invest in the Invesco Dynamic Biotechnology Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Should You Invest in the Invesco Dynamic Biotechnology Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
QIAGEN (QGEN) Q3 Earnings Beat Estimates, FY20 Guidance Up
by Zacks Equity Research
QIAGEN (QGEN) registeres robust revenue growth across geographies and both operating segments in Q3 despite the coronavirus-led economic crisis.
Qiagen (QGEN) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of 5.46% and 7.62%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Align's (ALGN) ClinCheck Suite Now Commercially Available
by Zacks Equity Research
Align Technology's (ALGN) ClinCheck treatment-planning software's commercial availability is expected to boost doctor performances due to ready availability of treatment plans.
Intersect ENT (XENT) Posts Preliminary Q3 Data, Dull Q4 View
by Zacks Equity Research
Intersect ENT (XENT) expects the strength in its product lines to have substantially boosted revenues in the third quarter.
The Zacks Analyst Blog Highlights: Edwards Lifesciences, QIAGEN, IDEXX, LHC and ResMed
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Edwards Lifesciences, QIAGEN, IDEXX, LHC and ResMed
3 MedTech Growth Stocks to Scoop Up Ahead of Q3 Earnings
by Zacks Equity Research
Here are three growth stocks from the MedTech space that investors can pick ahead of the quarterly releases.
AnaptysBio (ANAB) Jumps: Stock Rises 7.7%
by Zacks Equity Research
AnaptysBio (ANAB) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
IVERIC bio (ISEE) Catches Eye: Stock Jumps 6.8%
by Zacks Equity Research
IVERIC bio (ISEE) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
NeoGenomics (NEO) Looks Good: Stock Adds 5.5% in Session
by Zacks Equity Research
NeoGenomics (NEO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Boston Scientific Gets a Boost From MedSurg Arm Amid Coronavirus
by Zacks Equity Research
Within Endoscopy, Boston Scientific (BSX) believes that business recovery started since June.
Passage Bio (PASG) Looks Good: Stock Adds 5.4% in Session
by Zacks Equity Research
Passage Bio (PASG) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Abbott's New Antibody Test Gets FDA's EUA, Test Suite Expands
by Zacks Equity Research
Abbott's (ABT) latest antibody test is expected to give a clearer picture of the rate of recovery post coronavirus infection.
Here's Why You Should Hold on to NuVasive (NUVA) Stock Now
by Zacks Equity Research
Investors are optimistic about NuVasive (NUVA) on continued momentum across several recently-launched products as well as potential in its U.S. Surgical Support business.
Bruker Rides on Nano and MALDI Launches Despite Margin Debacle
by Zacks Equity Research
Bruker (BRKR) has several Bruker NANO products that are being assembled and tested in Malaysia.
Abbott's Data From Interim Clinical Study of ID NOW Positive
by Zacks Equity Research
Abbott's (ABT) recent data from an interim clinical study on its ID NOW COVID-19 rapid test reflects the test's capacity to deliver effective, consistent and reliable performance.
Bio-Rad (BIO) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Bio-Rad (BIO) is optimistic about maintaining robust testing portfolio along with strength in its Life Sciences business.
Evelo Biosciences (EVLO) Looks Good: Stock Adds 5.9% in Session
by Zacks Equity Research
Evelo Biosciences (EVLO) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Five Prime (FPRX) Looks Good: Stock Adds 5.1% in Session
by Zacks Equity Research
Five Prime (FPRX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
NuVasive's (NUVA) MaXcess Retractor Study Results Positive
by Zacks Equity Research
NuVasive's (NUVA) MaXcess retractor's ability to perform lateral surgery in various approaches, including prone position, is validated by favorable study outcome.
Has QIAGEN N.V. (QGEN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (QGEN) Outperforming Other Medical Stocks This Year?
Medtronic Announces U.S. Launch of Adaptix, Expands Portfolio
by Zacks Equity Research
Medtronic (MDT) introduces fully-navigated titanium implant procedure in the United States with the launch of Adaptix Interbody System.